Phase Ib trial (ex-US) of oral exenatide [ORMD 0901] for type 2 diabetes mellitus

Trial Profile

Phase Ib trial (ex-US) of oral exenatide [ORMD 0901] for type 2 diabetes mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Nov 2016 Status changed from recruiting to completed, according to an Oramed Pharmaceuticals media release.
    • 06 Jan 2016 As per an Oramed Pharmaceuticals media release, data from this trial is expected upon completion of this trial in the first quarter of 2016.
    • 06 Jan 2016 Status changed from planning to recruiting, as per Oramed Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top